Recent clinical trials are reshaping the treatment landscape for high‑risk myelodysplastic syndromes (HR‑MDS). In the Phase I/II TakeAim Leukemia study, the oral IRAK4/FLT3/CLK inhibitor emavusertib showed promising activity in patients whose disease had progressed after venetoclax or hypomethylating agents. Four of 13 evaluable participants achieved a measurable complete remission, with treatment durations ranging from one month to over eight months. Ongoing studies are testing emavusertib in combination with hypomethylating agents, BCL‑2 blockers, and BTK inhibitors to broaden its impact. A separate Phase II trial compared the NEDD8‑activating enzyme inhibitor pevonedistat plus azacitidine (AZA) against AZA alone in HR‑MDS, chronic myelomonocytic leukemia, and low‑blast AML patients who were naïve to hypomethylating therapy. The combination extended median overall survival to 23.9 months (vs 19.1 months with AZA) and median event‑free survival to 20.2 months (vs 14.8 months). Response rates also rose dramatically, with an overall response of 79 % and complete remissions in 52 % of patients, without added myelosuppression. Conversely, the selective RAR‑α agonist tamibarotene, tested with AZA in the SELECT‑MDS‑1 Phase III trial, failed to improve complete remission rates, underscoring that not all targeted approaches will succeed. Together, these findings highlight a wave of innovative therapies—some delivering clear survival benefits, others still needing refinement—as researchers strive to improve outcomes for those battling high‑risk MDS.
Read more